by Vincent Van der Wel | Aug 11, 2025 | Blog
Developing a medicine that is accessible for patients remains a big challenge, especially in areas like rare diseases or drug repurposing. Every day new papers are published with potential treatments in the scientific literature, but the path from lab to clinic is...
by Ivo De Nooijer | Jul 14, 2025 | Blog
Repurposing existing drugs for new indications has emerged as a powerful strategy in modern drug development. Yet, the business models that underpin successful repurposing ventures remain diverse and highly dependent on how intellectual property (IP) is managed. In...
by Hellen Houlleberghs | Jun 17, 2025 | Blog
A promising rare disease treatment supported by Orfenix. At Orfenix, we are dedicated to turning academic breakthroughs into life-changing therapies through efficient and socially responsible drug development. One of our key projects focuses on guanabenz, a promising...
by Barbara Van den Aarsen | May 22, 2025 | Blog
Clinical trials play a vital role in developing new treatments and medications. However, when children are involved, the process becomes significantly more complex. Children are considered a vulnerable population, requiring careful ethical, regulatory, and...
by Hellen Houlleberghs | Apr 14, 2025 | Blog
At Orfenix, our mission is to develop therapies for unmet medical needs. One such need is a treatment for pseudoxanthoma elasticum (PXE), a rare genetic disorder that significantly impacts patients’ lives. Heleen van Loenen, head of the Dutch PXE patient organisation,...
by Ivo De Nooijer | Mar 20, 2025 | Blog
We at Orfenix are committed to socially responsible pharmaceutical practices. These practices emphasize balancing innovation with accessibility, long-term pharmaceutical sustainability, and equity. These principles drive efforts to create strategic public-private...
